Fluorexetamine, also known as 2′-Fluoro-Deschloroketamine (2-FDCK) or FXE, is a dissociative research chemical that belongs to the arylcyclohexylamine class. It is a derivative of the popular dissociative drug ketamine, with a fluorine atom added to the molecule. Fluorexetamine has gained popularity in recent years due to its similarity to ketamine in terms of effects, but with a longer duration and less intense dissociation.
Fluorexetamine produces a range of effects depending on the dosage and method of administration. At lower doses, it can produce a stimulating and euphoric effect, similar to that of amphetamines. As the dosage increases, the effects become more dissociative, with users experiencing a sense of detachment from their surroundings and their own body. At higher doses, it can cause complete dissociation, resulting in a state of anaesthesia and unconsciousness. The effects of fluorexetamine are typically described as being smoother and less intense than those of ketamine, but with a longer duration.
As a research chemical, fluorexetamine has not yet been extensively studied, and there is little information available on its potential uses. However, due to its similarities to ketamine, it is believed that it may have potential in the fields of anaesthesia and pain management. Some users also report using fluorexetamine as a recreational drug, either alone or in combination with other substances.
As with all research chemicals, the safety profile of fluorexetamine is largely unknown, and there is a high risk of adverse effects, particularly at high dosages. Some users have reported experiencing respiratory depression, seizures, and other serious side effects. There is also a risk of addiction and dependence, particularly with regular or heavy use. It is important to use caution when using fluorexetamine, to start with a low dose, and to avoid combining it with other substances. Users should also ensure that they have access to appropriate medical support in case of an emergency.
There are no reviews yet.